TargetMol
PF-3758309, also known as PF-03758309, is a PAK4 inhibitor, is also a n orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity. PAK4 inhibitor PF-03758309 binds to PAK4, inhibiting PAK4 activity and cancer cell growth. PAK4, a serine/threonine kinase belonging to the p21-activated kinase (PAK) family, is often upregulated in a […]
More Information
Supplier Page
PF-06260933
2 mg
| Purity Not Available
TargetMol
PF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
More Information
Supplier Page
TargetMol
E6446
1 mg
| 99.41%
TargetMol
E6446 inhibits Toll-like receptor (TLR)7 and 9 signaling. E6446 works in a variety of human and mouse cell types and inhibits DNA-TLR9 interaction in vitro. When administered to mice, this compound suppress responses to challenge doses of cytidine-phosphate-guanidine (CpG)-containing DNA, which stimulates TLR9.
More Information
Supplier Page
Delamanid
100 mg
| Purity Not Available
TargetMol
Delamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall.
More Information
Supplier Page
TargetMol
TargetMol
Succinobucol is a novel phenolic antioxidant small molecule with anti-oxidant and anti-inflammatory properties. It designed to treat atherosclerosis of the blood vessels of the heart or coronary artery disease.
More Information
Supplier Page
AD80
1 mg
| 99.90%
TargetMol
Flumatinib
25 mg
| Purity Not Available
TargetMol
Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
More Information
Supplier Page
Flumatinib
10 mg
| Purity Not Available
TargetMol
Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
More Information
Supplier Page
